albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
HIPAA stands for the Health Insurance Portability and Accountability Act of 1996. It is a U.S. healthcare legislation to direct how patient data is used and includes two major rules which are privacy and security of data. The privacy rule protects people's rights to privacy and security rule determines how to protect people's privacy. According to the HIPAA Security Rule, it ensures that protected health information has three characteristics: confidentiality, availability, and integrity. Confidentiality indicates keeping the data confidential to prevent data loss or individuals who are unauthorized to access that protected health information. Availability allows people who are authorized to access the systems and networks when and where that information is in fact needed, such as natural disasters. In cases like this, protected health information is mostly backed up on to a separate server or printed out in paper copies, so people can access it. Lastly, integrity ensures not using inaccurate information and improperly modified data due to a bad design system or process to protect the permanence of the patient data. The consequences of using inaccurate or improperly modified data could become useless or even dangerous. Health Organizations of HIPAA also created administrative safeguards, physical safeguards, technical safeguards, to help protect the privacy of patients.
Drucker, Jens Holst and Svetlana Mojsov 2025: Member of the National Academy of Sciences (Section 42: Medical Physiology and Metabolism) 2025: Distinguished Medical Science Award by the National Library of Medicine - Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen 2025: Carothers Award from the American Chemical Society Delaware Section 2025: Helen Dean King Award of Wistar Institute in Philadelphia 2026: Member of the Macedonian Academy of Sciences and Arts 2026: Kimberly Prize in Biochemistry and Molecular Genetics 2026: Boulder Peptide Foundation Meinehofer Award 2026: King Faisal Prize in Medicine 2026: Broermann Medical Innovation Award - Matthias Tschöp, Svetlana Mojsov and Richard DiMarchi 2027: Elaine Redding Brinster Prize in Science or Medicine - Svetlana Mojsov and Lotte Bjerre Knudsen
== Sclera in animals == The cooperative eye hypothesis suggests that the pale sclera evolved as a method of nonverbal communication that makes it easier for one individual to identify where another individual is looking. In addition to this, the "cooperative eye hypothesis" expands on the proposal that white sclera are a sign of good health, being useful for mate selection. However, the cooperative eye hypothesis has been questioned based on correspondence between known eye gaze following certain behaviors like the stare-in-the-crowd effect and depigmentation patterns. There is also evidence to suggest that eye visibility promotes altruistic behavior by letting others know they are being watched. Animal researchers have found that, in the course of their domestication, dogs have also developed the ability to pick up visual cues from the eyes of humans. Dogs do not seem to use this form of communication with one another and only look for visual information from the eyes of humans. Chimpanzees have also been found to be able to discern gaze direction in humans, and are the only other animals found to do this thus far. Other mammals with white or pale sclera include chimpanzees, many orangutans, some gorillas, and bonobos. The eyes of all non-human primates have been thought to be dark with small, barely visible sclera, but recent research has suggested that white sclera are not uncommon in chimpanzees, and are also present in other mammals. Most non-human mammals are thought to have a darker sclera which conceals gaze direction.
The homozygous mutation causes prenatal onset of recurrent fractures of the ribs and long bones, demineralization, decreased ossification of the skull, and blue sclerae; it is clinically type II or type III. Family members who are heterozygous for OI XVI may have recurrent fractures, osteopenia and blue sclerae. Type XVII – OI caused by homozygous mutation in the SPARC gene on chromosome 5q33, causing a defect in the protein osteonectin, which leads to severe disease characterized by generalized platyspondyly, dependence on a wheelchair, and recurrent fractures. Type XVIII – OI caused by homozygous mutation in the FAM46A gene on chromosome 6q14.1. Characterized by congenital bowing of the long bones, Wormian bones, blue sclerae, vertebral collapse, and multiple fractures in the first years of life. Type XIX – OI caused by hemizygous mutation in the MBTPS2 gene on chromosome Xp22.12. Thus far, OI type XIX is the only known type of OI with an X-linked recessive pattern of inheritance, making it the only type that is more common in males than females. OI type XIX disrupts regulated intramembrane proteolysis, which is critical for healthy bone formation. Type XX – OI caused by homozygous mutation in the MESD gene on chromosome 15q25.1. Initial studies of type XX indicate that it may cause global developmental delay, a first among OI types. OI type XX disrupts the Wnt signaling pathway, which is thought to have a role in bone development. Type XXI – OI caused by homozygous mutation in the KDELR2 gene on chromosome 7p22.1.
Sources: en.wikipedia.org
The reaction 239Pu+48Ca has also been suggested as a means to produce 282Fl and 283Fl in the 5n and 4n channels respectively, but so far only the 3n channel leading to 284Fl has been observed. The Dubna team repeated their investigation of the 240Pu+48Ca reaction in 2017, observing three new consistent decay chains of 285Fl, another decay chain from this nuclide that may pass through some isomeric states in its daughters, a chain that could be assigned to 287Fl (likely from 242Pu impurities in the target), and some spontaneous fissions of which some could be from 284Fl, though other interpretations including side reactions involving evaporation of charged particles are also possible. The alpha decay of 284Fl to spontaneously fissioning 280Cn was finally observed by the Dubna team in 2024.
The primary adverse effect of any insulin product is hypoglycemia, or low blood sugar. Hypoglycemia can manifest as dizziness, disorientation, trouble speaking, and changes in mental status. In severe cases, hypoglycemia can lead to loss of consciousness if not treated. As lente insulin continues to be absorbed in the body for hours after use, these signs and symptoms may be delayed from the time of administration and begin with little or no warning.
== History == Athletes in ancient Greece were advised to consume large quantities of meat and wine. A number of herbal concoctions and tonics have been used by strong men and athletes since ancient times across cultures to try to increase their strength and stamina. In the 1910s, Eugen Sandow, widely considered to be the first modern bodybuilder in the West, advocated the use of dietary control to enhance muscle growth. Later, bodybuilder Earle Liederman advocated the use of "beef juice" or "beef extract" (basically, consommé) as a way to enhance muscle recovery. In the 1950s, with recreational and competitive bodybuilding becoming increasingly popular, Irvin P. Johnson began to popularize and market egg-based protein powders marketed specifically at bodybuilders and physical athletes. The 1970s and 1980s marked a dramatic increase in the growth of the bodybuilding supplement industry, fueled by the widespread use of modern marketing techniques and a marked increase in recreational bodybuilding. In October 1994, the Dietary Supplement Health and Education Act (DSHEA) was signed into law in the USA. Under DSHEA, responsibility for determining the safety of the dietary supplements changed from the government to the manufacturer, and supplements no longer required approval from the U.S. Food and Drug Administration (FDA) before distributing the products. Since that time, manufacturers did not have to provide FDA with the evidence to substantiate safety or effectiveness unless a new dietary ingredient was added.
Sources: en.wikipedia.org
=== A public-health approach === A common critical view holds that the war on drugs has been costly and ineffective largely because US federal and state governments have chosen the wrong methods, focusing on interdiction and punishment rather than regulation and treatment of drug abuse and addiction. In the US, current public health-oriented interventions include harm reduction, drug courts, and Law Enforcement Assisted Diversion (LEAD) programs which give police treatment or social services options rather than arrest with minor drug offenses. Harm reduction approaches include provision of sterile syringes, medically supervised injection sites (SIF), and availability of the opioid overdose-countering drug naloxone. As an alternative to imprisonment, drug courts in the US identify substance-abusing offenders and place them under strict court monitoring and community supervision, as well as provide them with long-term treatment services. According to a National Drug Court Institute report, 16.4% of the nation's drug court graduates are rearrested and charged with a felony within one year of completing the program; overall 44.1% of released prisoners end up back in prison within one year. The drug court program is also significantly cheaper than imprisonment. Annual per offender cost is $20,000–$50,000 for imprisonment, and $2,500–$4,000 in the drug court system. A survey by the Substance Abuse and Mental Health Services Administration (SAMHSA) found that substance abusers who remain in treatment longer are less likely to resume their former drug habits.
In 1859, the first scientifically documented dinosaur egg fossils were discovered in southern France by a Catholic priest and amateur naturalist named Father Jean-Jacques Pouech; he thought, however, that they were laid by giant birds. The first scientifically recognized dinosaur egg fossils were discovered serendipitously in 1923 by an American Museum of Natural History crew while looking for evidence of early humans in Mongolia. These eggs were mistakenly attributed to the locally abundant herbivore Protoceratops, but are now known to be Oviraptor eggs. Egg discoveries continued to mount all over the world, leading to the development of multiple competing classification schemes.
=== Constituents === Nutmeg consists of 25 to 40% fatty oils or triglycerides (nutmeg butter), 7 to 16% volatile oils, and 45 to 60% pulp or structural components like cellulose. The triglyceride part is mostly trimyristin, but triolein and trilinolein are also found in small amounts. The psychoactive component of nutmeg appears to be the volatile oil component, with most of the rest inactive in animals and humans. It consists 80% of a terpene fraction, 10 to 15% of an aromatic fraction, and the small remainder fatty acids. Turpentine, a fluid made from the resin mainly of pine trees, has a similar composition as the terpene fraction of nutmeg, but has no reputation for producing intoxicating effects. The aromatic fraction of nutmeg consists of a number of allylbenzenes (propenylbenzenes), mainly myristicin, elemicin, and safrole (these three 84–95%), but also including methyleugenol, methylisoeugenol, methoxyeugenol, isoeugenol, eugenol, and isoelemicin. A 20 gram amount of nutmeg contains about 210 mg myristicin, 70 elemicin, 39 mg safrole, as well as 3 to 18 mg each of the other compounds. Myristicin makes up approximately 1.3% of whole nutmeg and about 4 to 13% of the volatile oil fraction. Myristicin and elemicin have been thought to be nutmeg's psychoactive constituents, whereas safrole and the various eugenols seem to be inactive with regard to such effects. Though other nutmeg components are inactive, they might aid in the absorption of the active constituents.
Numerous studies have attempted to identify contributing factors for obesity in the United States. Common factors include an overconsumption of food and an insufficient amount of physical exercise. Only 20% of jobs require physical activity. Related factors that have been attributed to an increase in childhood obesity includes "food deserts." Food deserts are considered urban areas that do not have the stores or access to proper nutritional food required for a sustainably healthy diet. Certain examples of this would include cities, where transportation may be limited, and the only surrounding food available at an affordable price is limited to fast food. Food insecure individuals have turned to food banks, which in turn has led to a rise in obesity and diabetes within the food insecure community. Individuals in lower income areas are dependent on food banks and because of that are not getting foods that are high in nutrients. Food insecure individuals, who live in low-income communities experience higher rates of chronic disease, leading to healthcare costs which create more financial hardships.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.